<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OSMITROL- mannitol injection, solution </strong><br>Baxter Healthcare Corporation<br></p></div>
<h1>
<span class="Bold">OSMITROL Injection (Mannitol Injection, USP)</span><br><span class="Bold">in VIAFLEX Plastic Container</span><br><span class="Bold">For Therapeutic Use Only </span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_adea2c2e-9e16-434a-be4b-d6178851f60a"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">OSMITROL Injection (Mannitol Injection, USP) is a sterile, nonpyrogenic solution of Mannitol, USP in a single dose container for intravenous administration. It contains no antimicrobial agents. Mannitol** is a six carbon sugar alcohol prepared commercially by the reduction of dextrose. Although virtually inert metabolically in humans, it occurs naturally in fruits and vegetables. Mannitol is an obligatory osmotic diuretic. The pH is adjusted with sodium hydroxide or hydrochloric acid. Composition, osmolarity, and pH are shown in Table 1</p>
<table width="100%">
<col width="18%">
<col width="16%">
<col width="23%">
<col width="22%">
<col width="21%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (≥600 mOsmol/L) may cause vein damage.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Table 1</span></p></td>
<td class="Toprule" align="center"><p class="First">  </p></td>
<td class="Toprule" align="center"><p class="First">Composition</p></td>
<td class="Toprule"></td>
<td class="Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">Size (mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">**Mannitol, USP <br>(g/L)</p></td>
<td class="Botrule Lrule" align="center"><p class="First"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>Osmolarity <br>(mOsmol/L) (calc)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">pH</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">5% OSMITROL Injection <br>(5% Mannitol Injection, USP) </p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">1000</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">50</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">274</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.0 <br>(4.5 TO 7.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">10% OSMITROL Injection <br>(10% Mannitol Injection, USP) </p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">500</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">100</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">549</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.0 <br>(4.5 TO 7.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">15% OSMITROL Injection <br>(15% Mannitol Injection, USP) </p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">500</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">150</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">823</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.0 <br>(4.5 TO 7.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2" valign="middle"><p class="First">20% OSMITROL Injection <br>(20% Mannitol Injection, USP) </p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">250</p></td>
<td class="Botrule Lrule" align="center" rowspan="2" valign="middle"><p class="First">200</p></td>
<td class="Botrule Lrule" align="center" rowspan="2" valign="middle"><p class="First">1098</p></td>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle"><p class="First">5.0 <br>(4.5 TO 7.0)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">500</p></td></tr>
</tbody>
</table>
<div class="Figure">
<a name="id574"></a><img alt="Osmitrol Injection Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=image-01.jpg">
</div>
<p>The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_efd77aa6-6c9a-4b10-9d0e-f83bde48cfdc"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">OSMITROL Injection (Mannitol Injection, USP) is one of the nonelectrolyte, obligatory, osmotic diuretics. It is freely filterable at the renal glomerulus, only poorly reabsorbed by the renal tubule, not secreted by the tubule, and is pharmacologically inert. </p>
<p>Mannitol, when administered intravenously, exerts its osmotic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Only relatively small amounts of the dose administered is metabolized. Mannitol is readily diffused through the glomerulus of the kidney over a wide range of normal and impaired kidney function. In this fashion, approximately 80% of a 100 gram dose of mannitol will appear in the urine in three hours with lesser amounts thereafter. Even at peak concentrations, mannitol will exhibit less than 10% of tubular reabsorption and is not secreted by tubular cells. Mannitol will hinder tubular reabsorption of water and enhance excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate. </p>
<p>This increase in extracellular osmolarity effected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure, intracranial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and elevated intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_e3a4aa1d-3c44-4ccb-8ab1-229ea628bc49"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">OSMITROL Injection (Mannitol Injection, USP) is indicated for: </p>
<p>The promotion of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, in the prevention and/or treatment of the oliguric phase of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> before <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span> becomes established;</p>
<p>The reduction of intracranial pressure and treatment of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> by reducing brain <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>;</p>
<p>The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and</p>
<p>Promoting the urinary excretion of toxic substances.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_be68f4c9-877b-4354-9450-c97c2fde8d12"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">OSMITROL Injection (Mannitol Injection, USP) is contraindicated in patients with: </p>
<p>Well established <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> due to severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, </p>
<p>Severe <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span> or frank <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, </p>
<p>Active intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> except during craniotomy, </p>
<p>Severe <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, </p>
<p>Progressive renal damage or dysfunction after institution of mannitol therapy, including increasing <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and </p>
<p>Progressive <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span> after institution of mannitol therapy.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_2968fe92-ffcd-4253-bc5a-1b78fd592c75"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with severe impairment of renal function, a test dose should be utilized (see <span class="Bold">Dosage and Administration</span>). A second test dose may be tried if there is an inadequate response, but no more than two test doses should be attempted. </p>
<p>The obligatory diuretic response following rapid infusion of 15% or 20% mannitol injection may further aggravate preexisting hemoconcentration. Excessive loss of water and electrolytes may lead to serious imbalances. Serum sodium and potassium should be carefully monitored during mannitol administration. </p>
<p>If urine output continues to decline during mannitol infusion, the patient’s clinical status should be closely reviewed and mannitol infusion suspended if necessary. Accumulation of mannitol may result in overexpansion of the extracellular fluid which may intensify existing or latent <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. </p>
<p>Excessive loss of water and electrolytes may lead to serious imbalances. With continued administration of mannitol, loss of water in excess of electrolytes can cause <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>. Electrolyte measurements, including sodium and potassium, are therefore, of vital importance in monitoring the infusion of mannitol. </p>
<p>Osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, a reversible vacuolization of the tubules of unknown clinical significance, may proceed to severe irreversible <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, so that the renal function must be closely monitored during mannitol infusion.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_a036568f-06f7-4a71-942b-3bfe420c626f"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">The cardiovascular status of the patient should be carefully evaluated before rapidly administering mannitol since sudden expansion of the extracellular fluid may lead to fulminating <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. </p>
<p>Shift of sodium free intracellular fluid into the extracellular compartment following mannitol infusion may lower serum sodium concentration and aggravate preexisting <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. </p>
<p>By sustaining <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, mannitol administration may obscure and intensify inadequate hydration or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>. </p>
<p>Electrolyte free mannitol injections should not be given conjointly with blood. If it is essential that blood be given simultaneously, at least 20 mEq of sodium chloride should be added to each liter of mannitol solution to avoid pseudoagglutination. </p>
<p>When exposed to low temperatures, solutions of mannitol may crystallize. Concentrations greater than 15% have a greater tendency to crystallization. Inspect for crystals prior to administration. If crystals are visible, redissolve by warming the solution up to 70°C, with <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>. Allow the solution to cool to room temperature before reinspection for crystals. Administer intravenously using sterile, <span class="Bold">filter-type</span> administration set.</p>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_242e840e-40d4-4036-8877-030abd769793"></a><a name="section-6.1"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Although blood levels of mannitol can be measured, there is little if any clinical virtue in doing so. The appropriate monitoring of blood levels of sodium and potassium; degree of hemoconcentration or hemodilution, if any; indices of renal, cardiac and pulmonary function are paramount in avoiding excessive fluid and electrolyte shifts. The routine features of physical examination and clinical chemistries suffice in achieving an adequate degree of appropriate patient monitoring.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_5f30eb93-f624-4869-830b-5bde90aabf10"></a><a name="section-6.2"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_7e0ec789-33ff-4b5d-90ee-96167560a0cd"></a><a name="section-6.2.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_4bee329e-e511-44a5-b89c-81780112d05c"></a><a name="section-6.2.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category C</span></h4>
<p class="First">Animal reproduction studies have not been conducted with mannitol. It is also not known whether mannitol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Mannitol should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e6edb061-07fb-4e9b-8713-b0c28d0b703f"></a><a name="section-6.3"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when mannitol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ca10f94d-7c45-4464-acb9-a7d3666cf493"></a><a name="section-6.4"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children below the age of 12 have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_38157fa8-1d06-4c90-b439-26aae0b29bc8"></a><a name="section-6.5"></a><p></p>
<h2>Usage in Children</h2>
<p class="First">Dosage requirements for patients 12 years of age and under have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_8153ca12-ab4d-4a9d-9975-31dcb0f59fb9"></a><a name="section-6.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of OSMITROL Injection (Mannitol Injection, USP) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_15705cce-13e5-4563-a98e-ac06a06d2ffd"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Extensive use of mannitol over the last several decades has produced recorded adverse events, in a variety of clinical settings, that are isolated or idiosyncratic in nature. None of these adverse reactions have occurred with any great frequency nor with any security in attributing them to mannitol. </p>
<p>The inability to clearly exclude the drug related nature of such events in these isolated reports prompts the necessity to list the reactions that have been observed in patients during or following mannitol infusion. In this fashion, patients have exhibited <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span> and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> at the site of injection, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and angina-like <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>. </p>
<p>Of far greater clinical significance is a variety of events that are related to inappropriate recognition and monitoring of fluid shifts. These are not intrinsic adverse reactions to the drug but the consequence of manipulating osmolarity by any agency in a therapeutically inappropriate manner. Failure to recognize severe impairment of renal function with the high likelihood of nondiuretic response can lead to aggravated <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of tissues and increased vascular fluid load. Induced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in the presence of preexisting hemoconcentration and preexisting deficiency of water and electrolytes can lead to serious imbalances. Expansion of the extracellular space can aggravate cardiac decompensation or induce it in the presence of latent <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">Pulmonary congestion</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> can be seriously aggravated with the expansion of the extracellular and therefore intravascular fluid load. Hemodilution and dilution of the extracellular fluid space by osmotic shift of water can induce or aggravate preexisting <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. </p>
<p>If unrecognized, such fluid and/or electrolyte shift can produce the reported adverse reactions of <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, electrolyte loss, dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive cardiac failure</span>. </p>
<p>These are not truly adverse reactions to the drug and can be appropriately prevented by evaluation of degree of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> with a test dose response to mannitol when indicated; evaluation of <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>; sodium and potassium levels; hemodilution or hemoconcentration; and evaluation of renal, cardiac and pulmonary function at the onset of therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_53882d9c-1f78-4d08-933d-505eadc8a685"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">OSMITROL Injection (Mannitol Injection, USP) should be administered only by intravenous infusion. The total dosage, concentration, and rate of administration should be governed by the nature and severity of the condition being treated, fluid requirement, and urinary output. The usual adult dosage ranges from 20 to 100 g in a 24 hour period, but in most instances an adequate response will be achieved at a dosage of approximately 50 to 100 g in a 24 hour period. The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50 mL/hour. This outline of administration and dosage is only a general guide to therapy. </p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible. </p>
<p>Test Dose: A test dose of mannitol should be given prior to instituting OSMITROL Injection (Mannitol Injection, USP) therapy for patients with marked <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, or those believed to have inadequate renal function. Such a test dose may be approximately 0.2 g/kg body weight (about 75 mL of a 20% solution or 100 mL of a 15% solution) infused in a period of three to five minutes to produce a urine flow of at least 30 to 50 mL/hour. If urine flow does not increase, a second test dose may be given; if there is an inadequate response, the patient should be reevaluated. </p>
<p>Prevention of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span> (<span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>): When used during cardiovascular and other types of surgery, 50 to 100 g of mannitol as a 5, 10, or 15% solution may be given. The concentration will depend upon the fluid requirements of the patient. </p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>: The usual dose for treatment of <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> is 100 g administered as a 15 or 20% solution.</p>
<p>Reduction of Intraocular Pressure: A dose of 1.5 to 2.0 g/kg as a 20% solution (7.5 to 10 mL/kg) or as a 15% solution (10 to 13 mL/kg) may be given over a period as short as 30 minutes in order to obtain a prompt and maximal effect. When used preoperatively the dose should be given one to one and one-half hours before surgery to achieve maximal reduction of intraocular pressure before operation. </p>
<p>Reduction of Intracranial Pressure: Usually a maximum reduction in intracranial pressure in adults can be achieved with a dose of 0.25 g/kg given not more frequently than every six to eight hours. An osmotic gradient between the blood and cerebrospinal fluid of approximately 10 mOsmol will yield a satisfactory reduction in intracranial pressure. </p>
<p>Adjunctive Therapy for <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxications</span>: As an agent to promote <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxications</span>, 5%, 10%, 15% or 20% mannitol is indicated. The concentration will depend upon the fluid requirement and urinary output of the patient. </p>
<p>Measurement of glomerular filtration rate by creatinine clearance may be useful for determination of dosage. </p>
<p>All injections in VIAFLEX containers are intended for intravenous administration using sterile equipment. </p>
<p>The use of supplemental additive medication is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_3690bb83-5c82-4556-a461-e683e9d0877c"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">OSMITROL Injection (Mannitol Injection, USP) in VIAFLEX plastic containers is available as follows: </p>
<table width="100%">
<col width="13%">
<col width="12%">
<col width="20%">
<col width="55%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First"><span class="Bold">Code</span></p></td>
<td class="Toprule"><p class="First"><span class="Bold">Size (mL)</span></p></td>
<td class="Toprule"><p class="First"><span class="Bold">NDC</span></p></td>
<td class="Toprule"><p class="First"><span class="Bold">Product Name</span></p></td>
</tr>
<tr>
<td><p class="First"> 2D5604 </p></td>
<td><p class="First"> 1000 </p></td>
<td><p class="First"> 0338-0351-04 </p></td>
<td><p class="First"> 5% OSMITROL Injection (5% Mannitol Injection, USP) </p></td>
</tr>
<tr>
<td><p class="First"> 2D5613 </p></td>
<td><p class="First"> 500 </p></td>
<td><p class="First"> 0338-0353-03 </p></td>
<td><p class="First"> 10% OSMITROL Injection (10% Mannitol Injection, USP) </p></td>
</tr>
<tr>
<td><p class="First"> 2D5623 </p></td>
<td><p class="First"> 500 </p></td>
<td><p class="First"> 0338-0355-03 </p></td>
<td><p class="First"> 15% OSMITROL Injection (15% Mannitol Injection, USP) </p></td>
</tr>
<tr>
<td><p class="First"> 2D5632 </p></td>
<td><p class="First"> 250 </p></td>
<td><p class="First"> 0338-0357-02 </p></td>
<td rowspan="2"><p class="First"> 20% OSMITROL Injection (20% Mannitol Injection, USP) </p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"> 2D5633 </p></td>
<td class="Botrule"><p class="First"> 500 </p></td>
<td class="Botrule"><p class="First"> 0338-0357-03 </p></td>
</tr>
</tbody>
</table>
<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b6909b6c-6e90-4ddc-bc8a-f6461466ce61"></a><a name="section-10"></a><p></p>
<h1>DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINER</h1>
<p class="First"><span class="Bold">Warning:</span> Do not use plastic container in series connections. Such use could result in <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6146e1ba-620d-4376-9b6c-9151154815c6"></a><a name="section-10.1"></a><p></p>
<h2>To Open </h2>
<p class="First">Tear overwrap down side at slit and remove solution container.  Visually inspect the container.  If the outlet port protector is damaged, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">detached</span>, or not present, discard container as solution path <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed.  This is normal and does not affect the solution quality or safety.  The opacity will diminish gradually.  Check for minute leaks by squeezing inner bag firmly.  If leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99fab18b-67fb-4bef-a6bf-73d22aeb8675"></a><a name="section-10.2"></a><p></p>
<h2>Preparation for Administration </h2>
<dl>
<dt>•</dt>
<dd>Suspend container from eyelet support. </dd>
<dt>•</dt>
<dd>Remove plastic protector from outlet port at bottom of container. </dd>
<dt>•</dt>
<dd>Attach administration set. Refer to complete directions accompanying set.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f166dbe-003b-4319-ad00-5ae94191520c"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Baxter Healthcare Corporation </span></p>
<p>Deerfield, IL 60015 USA</p>
<p>Printed in USA</p>
<p>07-19-73-134</p>
<p>Rev. May 2014</p>
<p>Baxter, Osmitrol, Viaflex, and PL 146 are trademarks of Baxter International Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_8e070e70-5025-4457-bfdd-3e2426cdd921"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id727"></a><img alt="Osmitrol Injection Representative Container Label NDC 0338-0351-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=image-02.jpg"><p class="MultiMediaCaption">Container Label </p>
</div>
<p class="First">Container Label </p>
<p><span class="Bold">2D5604</span><br><span class="Bold">NDC 0338-0351-04</span></p>
<p><span class="Bold">5% OSMITROL</span><br><span class="Bold">Injection</span><br><span class="Bold">(5% Mannitol</span><br><span class="Bold">Injection USP)</span></p>
<p><span class="Bold">1000 mL</span></p>
<p>EACH 100 mL CONTAINS 5 g MANNITOL USP pH ADJUSTED WITH<br>SODIUM HYDROXIDE OR HYDROCHLORIC ACID pH 5.0 (4.5 TO 7.0)<br>OSMOLARITY 274 mOsmol/L (CALC) STERILE NONPYROGENIC<br>SINGLE DOSE CONTAINER OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY<br>AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE AND<br>INSPECT INNER BAG WHICH MAINTAINS PRODUCT <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> DISCARD IF<br>LEAKS ARE FOUND DO NOT ADMINISTER SIMULTANEOUSLY WITH BLOOD<br>MUST NOT BE USED IN SERIES CONNECTIONS DO NOT USE UNLESS<br>SOLUTION IS CLEAR <span class="Bold">RX ONLY </span>STORE UNIT IN MOISTURE BARRIER<br>OVERWRAP AT ROOM TEMPERATURE (25<span class="Bold">°</span>C/77<span class="Bold">º</span>F) UNTIL READY TO USE<br>AVOID EXCESSIVE HEAT SEE INSERT</p>
<p>VIAFLEX CONTAINER<br>PL 146 PLASTIC</p>
<p>FOR PRODUCT INFORMATION<br>1-800-933-0303</p>
<p>BAXTER OSMITROL VIAFLEX<br>AND PL 146 ARE TRADEMARKS OF<br>BAXTER INTERNATIONAL INC </p>
<p><span class="Bold">BAXTER HEALTHCARE CORPORATION</span><br>DEERFIELD IL 60015 USA<br>MADE IN USA</p>
<p><a name="id128991039"></a><img alt="Osmitrol Injection Representative Carton Label  NDC 0338-0351-04" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=Osmitrol%20Injection%20Representative%20Carton%20Label%20NDC%200338-0351-02.jpg">Carton Label </p>
<p>2D5604X   14-1000 ML <br>VIAFLEX CONTAINER </p>
<p>5% OSMITROL INJECTION <br>5% MANNITOL INJECTION, USP </p>
<p>EXP <br>XXXXX </p>
<p>SECONDARY BAR CODE<br>(17) YYMM00 (10) XXXXX </p>
<p>LOT <br>XXXXX </p>
<p>PRIMARY BAR CODE<br>(01) 50303380351041 </p>
<p><a name="id-1698077092"></a><img alt="Osmitrol Injection Representative Container Label  NDC 0338-053-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=Osmitrol%20Injection%20Representative%20Container%20Label%20NDC%200338-053-03.jpg">Container Label </p>
<p><span class="Bold">2D5613</span><br><span class="Bold">NDC 0338-0353-03</span></p>
<p><span class="Bold">10% OSMITROL</span><br><span class="Bold">Injection</span><br><span class="Bold">(10% Mannitol</span><br><span class="Bold">Injection USP)</span></p>
<p><span class="Bold">500 mL</span></p>
<p>EACH 100 mL CONTAINS 10 g MANNITOL USP pH <br>ADJUSTED WITH SODIUM HYDROXIDE OR HYDROCHLORIC ACID <br>pH 5.0 (4.5 TO 7.0) OSMOLARITY 549 <br>mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE <br>CONTAINER OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY<br>AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS <br>SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT <br><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> DISCARD IF LEAKS ARE FOUND DO NOT <br>ADMINISTER SIMULTANEOUSLY WITH BLOOD MUST NOT BE <br>USED IN SERIES CONNECTIONS DO NOT USE UNLESS<br>SOLUTION IS CLEAR <span class="Bold">RX ONLY </span>STORE UNIT IN MOISTURE <br>BARRIER OVERWRAP AT ROOM TEMPERATURE (25<span class="Bold">°</span>C/77<span class="Bold">º</span>F) <br>UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT</p>
<p>VIAFLEX CONTAINER<br>PL 146 PLASTIC</p>
<p>FOR PRODUCT INFORMATION<br>1-800-933-0303</p>
<p>BAXTER OSMITROL VIAFLEX<br>AND PL 146 ARE TRADEMARKS OF<br>BAXTER INTERNATIONAL INC </p>
<p><span class="Bold">BAXTER HEALTHCARE CORPORATION</span><br>DEERFIELD IL 60015 USA<br>MADE IN USA</p>
<p><a name="id-1511906496"></a><img alt="Osmitrol Injection Representative Carton Label  NDC 0338-0353-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=Osmitrol%20Injection%20Representative%20Carton%20Label%20NDC%200338-0353-03.jpg">Carton Label </p>
<p>2D5613Q   24-500 ML</p>
<p>VIAFLEX CONTAINER</p>
<p>10% OSMITTROL INJECTION<br>10% OSMITROL INJECTION, USP</p>
<p>EXP<br>XXXXX</p>
<p>SECONDARY BAR CODE<br>(17) YYMM00  (10) XXXXX</p>
<p>LOT<br>XXXXX</p>
<p>PRIMARY BAR CODE<br>(01) 50303380353038</p>
<p><a name="id638765289"></a><img alt="Osmitrol Injection Representative Container Label  NDC 0338-0355-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=Osmitrol%20Injection%20Representative%20Container%20Label%20NDC%200338-0355-03.jpg">Container Label </p>
<p><span class="Bold">2D5623</span><br><span class="Bold">NDC 0338-0355-03</span></p>
<p><span class="Bold">15% OSMITROL</span><br><span class="Bold">Injection</span><br><span class="Bold">(15% Mannitol</span><br><span class="Bold">Injection USP)</span></p>
<p><span class="Bold">500 mL</span></p>
<p>EACH 100 mL CONTAINS 15 g MANNITOL USP pH ADJUSTED WITH <br>SODIUM HYDROXIDE OR HYDROCHLORIC ACID  pH 5.0 (4.5 TO 7.0) <br>OSMOLARITY 823 mOsmol/L (CALC) HYPERTONIC MAY CAUSE<br>VEIN DAMAGE STERILE NONPYROGENIC SINGLE DOSE CONTAINER <br>OSMOTIC DIURETIC DOSAGE INTRAVENOUSLY AS DIRECTED BY A <br>PHYSICIAN USING A <span class="Bold">FILTER TYPE</span> SET SEE DIRECTIONS CAUTIONS <br>SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS PRODUCT <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> <br>DISCARD IF LEAKS ARE FOUND DO NOT ADMINISTER SIMULTANEOUSLY <br>WITH BLOOD MUST NOT BE USED IN SERIES CONNECTIONS DO NOT <br>USE UNLESS SOLUTION IS CLEAR  IF CRYSTALS ARE VISIBLE REDISSOLVE<br>BY WARMING UNIT TO 70°C/158°F WITH <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">AGITATION</span>  COOL TO ROOM<br>TEMPERATURE AND REINSPECT FOR CRYSTALS BEFORE INFUSION<br><span class="Bold">RX ONLY </span>STORE UNIT IN MOISTURE BARRIER OVERWRAP AT ROOM <br>TEMPERATURE (25<span class="Bold">°</span>C/77<span class="Bold">º</span>F) UNTIL READY TO USE AVOID EXCESSIVE <br>HEAT SEE INSERT</p>
<p>VIAFLEX CONTAINER<br>PL 146 PLASTIC</p>
<p>FOR PRODUCT INFORMATION<br>1-800-933-0303</p>
<p>BAXTER OSMITROL VIAFLEX<br>AND PL 146 ARE TRADEMARKS OF<br>BAXTER INTERNATIONAL INC </p>
<p><span class="Bold">BAXTER HEALTHCARE CORPORATION</span><br>DEERFIELD IL 60015 USA<br>MADE IN USA</p>
<p><a name="id275528624"></a><img alt="Osmitrol Injection Representative Carton Label  NDC 0338-0355-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=Osmitrol%20Injection%20Representative%20Carton%20Label%20NDC%200338-0355-03.jpg">Carton Label </p>
<p>2D5623Q   24-500 ML<br>VIAFLEX CONTAINER</p>
<p>15% OSMITROL INJECTION<br>15% OSMITROL INJECTION, USP</p>
<p>EXP<br>XXXXX</p>
<p>SECONDARY BAR CODE<br>(17) YYMM00  (10) XXXXX</p>
<p>LOT<br>XXXXX</p>
<p>PRIMARY BAR CODE<br>(01) 50303380355032</p>
<p><a name="id1733270105"></a><img alt="Osmitrol Injection Representative Container Label  NDC 0338-0357-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=Osmitrol%20Injection%20Representative%20Container%20Label%20NDC%200338-0357-03.jpg">Container Label </p>
<p><span class="Bold">LOT  EXP</span></p>
<p><span class="Bold">2D5632</span><br><span class="Bold">NDC 0338-0357-02</span></p>
<p><span class="Bold">20% OSMITROL Injection</span><br><span class="Bold">(20% Mannitol Injection USP)</span></p>
<p><span class="Bold">250 mL </span>EACH 100 mL CONTAINS <br>15 g MANNITOL USP <br>pH ADJUSTED WITH SODIUM HYDROXIDE OR <br>HYDROCHLORIC ACID  pH 5.0 (4.5 TO 7.0) <br>OSMOLARITY 1098 mOsmol/L (CALC) <br>HYPERTONIC MAY CAUSE VEIN DAMAGE <br>STERILE NONPYROGENIC SINGLE DOSE <br>CONTAINER OSMOTIC DIURETIC DOSAGE<br>INTRAVENOUSLY AS DIRECTED BY A <br>PHYSICIAN USING A <span class="Bold">FILTER TYPE</span> SET SEE <br>DIRECTIONS CAUTIONS SQUEEZE AND <br>INSPECT INNER BAG WHICH MAINTAINS <br>PRODUCT <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> DISCARD IF LEAKS ARE <br>FOUND DO NOT ADMINISTER <br>SIMULTANEOUSLY WITH BLOOD MUST NOT BE <br>USED IN SERIES CONNECTIONS DO NOT USE <br>UNLESS SOLUTION IS CLEAR  IF <br>CRYSTALS ARE VISIBLE REDISSOLVE BY <br>WARMING UNIT TO 70°C/158°F WITH <br><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">AGITATION</span>  COOL TO ROOM TEMPERATURE <br>AND REINSPECT FOR CRYSTALS BEFORE <br>INFUSION<span class="Bold"> RX ONLY </span>STORE UNIT IN <br>MOISTURE BARRIER OVERWRAP AT ROOM <br>TEMPERATURE (25<span class="Bold">°</span>C/77<span class="Bold">º</span>F) UNTIL READY TO <br>USE AVOID EXCESSIVE HEAT SEE INSERT</p>
<p>VIAFLEX CONTAINER PL 146 PLASTIC</p>
<p>FOR PRODUCT INFORMATION<br>1-800-933-0303</p>
<p>BAXTER OSMITROL VIAFLEX<br>AND PL 146 ARE TRADEMARKS OF<br>BAXTER INTERNATIONAL INC </p>
<p><span class="Bold">BAXTER HEALTHCARE CORPORATION</span><br>DEERFIELD IL 60015 USA<br>MADE IN USA</p>
<p><a name="id-1896268459"></a><img alt="Osmitrol Injection Representative Carton Label  NDC 0338-0357-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d914965-7001-45cb-ba51-d7c5964b05bc&amp;name=Osmitrol%20Injection%20Representative%20Carton%20Label%20NDC%200338-0357-02.jpg">Carton Label </p>
<p>2D5623Q   36-500 ML<br>VIAFLEX CONTAINER</p>
<p>20% OSMITROL INJECTION<br>20% OSMITROL INJECTION, USP</p>
<p>EXP<br>XXXXX</p>
<p>SECONDARY BAR CODE<br>(17) YYMM00  (10) XXXXX</p>
<p>LOT<br>XXXXX</p>
<p>PRIMARY BAR CODE<br>(01) 50303380357029</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSMITROL 		
					</strong><br><span class="contentTableReg">mannitol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0351</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MANNITOL</strong> (MANNITOL) </td>
<td class="formItem">MANNITOL</td>
<td class="formItem">5 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0351-04</td>
<td class="formItem">1000 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA013684</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSMITROL 		
					</strong><br><span class="contentTableReg">mannitol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0353</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MANNITOL</strong> (MANNITOL) </td>
<td class="formItem">MANNITOL</td>
<td class="formItem">10 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0353-03</td>
<td class="formItem">500 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0338-0353-04</td>
<td class="formItem">1000 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem">06/08/1964</td>
<td class="formItem">04/01/2010</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA013684</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSMITROL 		
					</strong><br><span class="contentTableReg">mannitol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0355</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MANNITOL</strong> (MANNITOL) </td>
<td class="formItem">MANNITOL</td>
<td class="formItem">15 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0355-03</td>
<td class="formItem">500 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA013684</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OSMITROL 		
					</strong><br><span class="contentTableReg">mannitol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0338-0357</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MANNITOL</strong> (MANNITOL) </td>
<td class="formItem">MANNITOL</td>
<td class="formItem">20 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0338-0357-02</td>
<td class="formItem">250 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0338-0357-03</td>
<td class="formItem">500 mL in 1 BAG; Combination Product Type = C112160</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA013684</td>
<td class="formItem">06/08/1964</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(005083209)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">059140764</td>
<td class="formItem">MANUFACTURE(0338-0351, 0338-0353, 0338-0355, 0338-0357), ANALYSIS(0338-0351, 0338-0353, 0338-0355, 0338-0357), PACK(0338-0351, 0338-0353, 0338-0355, 0338-0357), LABEL(0338-0351, 0338-0353, 0338-0355, 0338-0357), STERILIZE(0338-0351, 0338-0353, 0338-0355, 0338-0357)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Healthcare Corporation</td>
<td class="formItem"></td>
<td class="formItem">194684502</td>
<td class="formItem">ANALYSIS(0338-0351, 0338-0353, 0338-0355, 0338-0357)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>57c99c24-bbd8-4b9d-b29c-67e2c2d7a049</div>
<div>Set id: 0d914965-7001-45cb-ba51-d7c5964b05bc</div>
<div>Version: 5</div>
<div>Effective Time: 20090911</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
